HFM NEWS
FEATURED NEWS
Are You Utilizing Your Resources? Learn how your HTC PT can help you!
Learn the many ways physical therapists provide support for bleeding disorder patients....
HFM partners with Save One Life for Women and Girls Initiative
HFM and Save One Life are partnering to support the unmet needs...
Update on Recall of Bayer Kogenate FS from National Organizations
Patient organizations are in ongoing communication with manufacturer...
National Joint Statement on Recall of Bayer Kogenate FS Lots
Last week, Bayer announced the recall of two lots of Kogenate® FS...
- All
- Advocacy
- Camp
- Featured News
- Health Education
- Medical Advisory
Are You Utilizing Your Resources? Learn how your HTC PT can help you!
Learn the many ways physical therapists provide support for bleeding disorder patients.
HFM partners with Save One Life for Women and Girls Initiative
HFM and Save One Life are partnering to support the unmet needs of women and girls with bleeding disorders across the world.
Update on Recall of Bayer Kogenate FS from National Organizations
Patient organizations are in ongoing communication with manufacturer
National Joint Statement on Recall of Bayer Kogenate FS Lots
Last week, Bayer announced the recall of two lots of Kogenate® FS antihemophilic factor (recombinant) 2000 IU vials. That highly concerning announcement has raised many questions on the part of both national organizations and community members.
Medical Advisory: Bayer Announces Recall of Two Lots of Kogenate FS
July 19, 2019 Bayer has announced a recall of two lots of Kogenate® FS 2000 IU vials.
Educating, Equipping, and Empowering Women with Hemophilia
Shellye Horowitz reviews the birth of HFM’s National Conference for Women with Hemophilia and the movement to ensure women with hemophilia receive proper medical care.
Ending Period Poverty
Oscar winning documentary shines light on a cause close to the bleeding disorders community.
Worried About Your Child Getting Homesick?
Planning to send your child to camp this summer? Learn a few tips to help you child overcome feeling homesick from one of camp’s HTC social workers.
How Will the Midterm Election Results Affect Healthcare in Michigan?
As the 2019 legislative cycle begins, HFM will be monitoring the introduction of bills and assessing their possible impact on the bleeding disorders community
Michigan Passes Medicaid Work Requirements Bill
The bill also includes exemptions for disability caretakers, parents of children under six, pregnant women, people receiving disability benefits, and those who are medically frail, which includes patients diagnosed with hemophilia, VWD, and other factor deficiencies.
Children’s Special Health Care Services: Maintaining Access to Care for the Bleeding Disorders Community
CSHCS covers people under the age of 21 with a qualifying medical condition. However, the age limitation is waived for patients with certain blood clotting disorders (hemophilia and other bleeding disorders) and cystic fibrosis.
Patient Advocacy Groups Work to Reduce the Impact of Out-of-Pocket Expenses
This legislation would require insurance plans to offer a copay only option, which would not require patients to reach a deductible before their insurance begins to pay a portion of the cost.
What is an Accumulator Adjustment Program?
Beginning January 2018, a few health plans, specifically high deductible plans offered by self-insured employer groups, have changed the way they calculate copays for patients using these cards.
It’s a Great Time to Review Your Insurance Plan for 2019
A few things to keep in mind! Do you depend on factor co-pay assistance? If so, you should know that some insurance plans have changed …
CSL Behring Discontinues Production and Distribution of Monoclate-P®
If you are currently using Monoclate-P®, please contact your physician or hemophilia treatment center to learn about other options that are available to you for treatment.
Genentech Issues Statement on Hemlibra
If you have questions or concerns, please reach out to Genentech and/or your physician.
Alnylam Suspends Fitusiran Dosing due to Thrombotic Event
The Company has suspended dosing in all ongoing fitusiran studies pending further review of the safety event and development of a risk mitigation strategy.
